knowledge -WSS

knowledge

author：Wikipedia 2025-09-27 10:46:17 - browse：354

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

LONDON — A U.K. government agency on Tuesday said that it won’t recommend Eli Lilly’s Mounjaro — part of a new class of medications that help patients lose weight — for people with type 2 diabetes without additional evidence.

Mounjaro, also known as tirzepatide, has U.S. approval for type 2 diabetes and is expected to win the regulatory green light for obesity later this year. It is one of several medications, along with Wegovy and Ozempic from Novo Nordisk, that have shown dramatic weight loss results, creating a surge in demand and blockbuster sales expectations.

But in draft guidance, the U.K.’s National Institute for Health and Care Excellence, which assesses the cost-effectiveness of medications, said it had asked Lilly for more data “to address the uncertainties in the clinical evidence, when compared to all relevant alternative treatments.” NICE recommendations are used by the National Health Service to determine whether to provide certain medications.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Researchers separate signal from noise in heart wearable data

hotspot

WSS

A biotech analyst on neuroscience, placebo effect, not over

Naloxone nonprofit donates 200,000 doses after FDA approval

Lindsay Lohan welcomes 1st child with husband Bader Shammas

Emergent cuts jobs, executive role in business shake

American woman, child freed after being kidnapped in Haiti last month

Friends ask where James Watson's attitudes about race came from

hotspot

knowledge

Wikipedia

Apple is now the first public company to be valued at $3 trillion

Wayne Brady comes out as pansexual: 'Free to love whomever I want'

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Maui's cultural, historic landmarks damaged in the devastating wildfires

The cancer drug shortage isn’t new — and neither are the solutions

For Cytokinetics, FDA rejection of heart drug would help, not hinder

How one medical school became remarkably diverse

Couple fighting to bring baby home from Mexico are finally reunited

Jerome Adams on the need for new antivirals for Covid

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

focus

Drastic changes should bring profitability, startup health insurers say

Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA

The best solution to the drug shortages problem

Jack Smith previously got search warrant for Trump's Twitter, new court docs show

DOJ, FTC to increase scrutiny of all types of health care mergers

For Cytokinetics, FDA rejection of heart drug would help, not hinder

Wikipedia

hotspot

hotspot

entertainment